As it is effective in HER2+ breast cancer patients in combination with Trastuzumab [37], a phase III trial (JACOB) is ongoing, in which HER2+ metastatic gastric cancer patients will receive Pertuzumab or placebo, in combination with Trastuzumab and chemotherapy. Here, ERBB2 is linked to breast cancer.